To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
ConditionGlabellar Lines
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19-65
SponsorHuons Biopharma
About this trial
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Eligibility criteria
Qualifiers
19 Years to 65 Years(Adult, Older Adult)
2(Moderate) and/or above of Facial Wrinkle Scale (FWS) score at frown in investigator's live assessment.
Subject who signed voluntarily in informed consent form and fully understood about this clinical trial.
Disqualifiers
Subject who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
History of bleeding disorder
Infection, dermatological condition or scar at the treatment injection sites
Subject who has marked facial asymmetry
Trial design
Treatments tested in this trial
- HU-045
- Xeomin®
Treatment groups
312 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov